JP2008534592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534592A5 JP2008534592A5 JP2008504152A JP2008504152A JP2008534592A5 JP 2008534592 A5 JP2008534592 A5 JP 2008534592A5 JP 2008504152 A JP2008504152 A JP 2008504152A JP 2008504152 A JP2008504152 A JP 2008504152A JP 2008534592 A5 JP2008534592 A5 JP 2008534592A5
- Authority
- JP
- Japan
- Prior art keywords
- bazedoxifene
- weight
- tablet
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960000817 bazedoxifene Drugs 0.000 claims 16
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 239000000047 product Substances 0.000 claims 13
- ORUUBRMVQCKYHB-UHFFFAOYSA-N butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol Chemical compound OC(=O)CCC(O)=O.C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 ORUUBRMVQCKYHB-UHFFFAOYSA-N 0.000 claims 9
- 239000010410 layer Substances 0.000 claims 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 6
- OMZAMQFQZMUNTP-UHFFFAOYSA-N acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol Chemical compound CC(O)=O.C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 OMZAMQFQZMUNTP-UHFFFAOYSA-N 0.000 claims 6
- 229960003713 bazedoxifene acetate Drugs 0.000 claims 6
- 239000002775 capsule Substances 0.000 claims 6
- 229960004981 desvenlafaxine succinate Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 6
- 239000007962 solid dispersion Substances 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 206010003694 Atrophy Diseases 0.000 claims 4
- 208000001640 Fibromyalgia Diseases 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 230000037444 atrophy Effects 0.000 claims 4
- 230000036765 blood level Effects 0.000 claims 4
- 239000013066 combination product Substances 0.000 claims 4
- 229940127555 combination product Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229940011871 estrogen Drugs 0.000 claims 4
- 239000000262 estrogen Substances 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 206010060800 Hot flush Diseases 0.000 claims 3
- 239000011247 coating layer Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66690205P | 2005-03-31 | 2005-03-31 | |
| PCT/US2006/010335 WO2006104791A1 (en) | 2005-03-31 | 2006-03-22 | O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008534592A JP2008534592A (ja) | 2008-08-28 |
| JP2008534592A5 true JP2008534592A5 (enExample) | 2009-04-02 |
Family
ID=36716648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504152A Withdrawn JP2008534592A (ja) | 2005-03-31 | 2006-03-22 | Ｏ−デスメチルベンラファキシンおよびバゼドキシフェンの組み合わせ生成物およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20060223791A1 (enExample) |
| EP (1) | EP1863464B1 (enExample) |
| JP (1) | JP2008534592A (enExample) |
| KR (1) | KR20070116607A (enExample) |
| CN (1) | CN101151026A (enExample) |
| AR (1) | AR052955A1 (enExample) |
| AT (1) | ATE447943T1 (enExample) |
| AU (1) | AU2006229869A1 (enExample) |
| BR (1) | BRPI0608754A2 (enExample) |
| CA (1) | CA2601898A1 (enExample) |
| CR (1) | CR9392A (enExample) |
| DE (1) | DE602006010343D1 (enExample) |
| ES (1) | ES2335919T3 (enExample) |
| GT (1) | GT200600127A (enExample) |
| IL (1) | IL185864A0 (enExample) |
| MX (1) | MX2007012167A (enExample) |
| NO (1) | NO20074559L (enExample) |
| PE (1) | PE20061336A1 (enExample) |
| RU (1) | RU2007132852A (enExample) |
| TW (1) | TW200719883A (enExample) |
| WO (1) | WO2006104791A1 (enExample) |
| ZA (1) | ZA200708323B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050227966A1 (en) * | 2004-04-08 | 2005-10-13 | Wyeth | Bazedoxifene acetate formulations |
| CN101223129A (zh) * | 2005-07-15 | 2008-07-16 | 惠氏公司 | 高度选择性血清素和去甲肾上腺素双重再摄取抑制剂和其用途 |
| US7687520B2 (en) | 2005-07-15 | 2010-03-30 | Wyeth Llc | Serotonin and norepinephrine reuptake inhibitors and uses thereof |
| US7595340B2 (en) | 2005-07-15 | 2009-09-29 | Wyeth | Serotonin and norepinephrine reuptake inhibitor and uses thereof |
| TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
| AU2007325207A1 (en) * | 2006-11-29 | 2008-06-05 | Wyeth | Estrogen/ serm and estrogen/ progestin bi-layer tablets |
| BRPI0812501A2 (pt) * | 2007-07-12 | 2015-06-16 | Reddys Lab Ltd Dr | O-desmetil venlafaxina |
| CZ302358B6 (cs) * | 2007-07-25 | 2011-03-30 | Zentiva, A. S. | Nové soli bazedoxifenu |
| CN101584696A (zh) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| EP2552419A2 (en) | 2010-03-31 | 2013-02-06 | Wockhardt Limited | Modified release dosage form comprising desvenlafaxine or salts thereof |
| EP2407467A1 (de) * | 2010-07-14 | 2012-01-18 | Sandoz Ag | Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure |
| WO2012140577A1 (en) * | 2011-04-12 | 2012-10-18 | Lupin Limited | Modified release pharmaceutical compositions of desvenlafaxine |
| WO2013182170A1 (en) * | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate |
| CN112754999A (zh) * | 2021-01-23 | 2021-05-07 | 郑州泰丰制药有限公司 | 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法 |
| CN113368075A (zh) * | 2021-06-29 | 2021-09-10 | 郑州泰丰制药有限公司 | 一种醋酸巴多昔芬片及其制备方法 |
| CN120531695A (zh) * | 2023-08-03 | 2025-08-26 | 常山凯捷健生物药物研发（河北）有限公司 | 一种包含取代的吲哚-5-酚衍生物的药物组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| EP1311293A2 (en) * | 2000-07-06 | 2003-05-21 | Wyeth | Combinations of ssri and estrogenic agents |
| AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| ATE369330T1 (de) * | 2001-02-12 | 2007-08-15 | Wyeth Corp | O-desmethyl-venlafaxine succinat salz |
| US20040063692A1 (en) * | 2002-06-13 | 2004-04-01 | Wyeth | Bazedoxifene treatment regimens |
| US20050175698A1 (en) * | 2004-02-06 | 2005-08-11 | Wyeth | Multiparticulate O-desmethylvenlafaxine salts and uses thereof |
| AR054833A1 (es) * | 2005-07-15 | 2007-07-18 | Wyeth Corp | Formas de dosificacion de liberacion retardada oral altamemte biodisponibles de succinato de o-desmetilvenlafaxina |
-
2006
- 2006-03-22 RU RU2007132852/15A patent/RU2007132852A/ru not_active Application Discontinuation
- 2006-03-22 DE DE602006010343T patent/DE602006010343D1/de active Active
- 2006-03-22 BR BRPI0608754-0A patent/BRPI0608754A2/pt not_active IP Right Cessation
- 2006-03-22 CN CNA2006800102992A patent/CN101151026A/zh active Pending
- 2006-03-22 AT AT06739215T patent/ATE447943T1/de not_active IP Right Cessation
- 2006-03-22 ES ES06739215T patent/ES2335919T3/es active Active
- 2006-03-22 KR KR1020077021609A patent/KR20070116607A/ko not_active Withdrawn
- 2006-03-22 WO PCT/US2006/010335 patent/WO2006104791A1/en not_active Ceased
- 2006-03-22 MX MX2007012167A patent/MX2007012167A/es active IP Right Grant
- 2006-03-22 JP JP2008504152A patent/JP2008534592A/ja not_active Withdrawn
- 2006-03-22 AU AU2006229869A patent/AU2006229869A1/en not_active Abandoned
- 2006-03-22 EP EP06739215A patent/EP1863464B1/en not_active Not-in-force
- 2006-03-22 CA CA002601898A patent/CA2601898A1/en not_active Abandoned
- 2006-03-22 US US11/386,420 patent/US20060223791A1/en not_active Abandoned
- 2006-03-27 TW TW095110550A patent/TW200719883A/zh unknown
- 2006-03-29 AR ARP060101219A patent/AR052955A1/es unknown
- 2006-03-29 PE PE2006000349A patent/PE20061336A1/es not_active Application Discontinuation
- 2006-03-29 GT GT200600127A patent/GT200600127A/es unknown
-
2007
- 2007-09-10 IL IL185864A patent/IL185864A0/en unknown
- 2007-09-10 NO NO20074559A patent/NO20074559L/no not_active Application Discontinuation
- 2007-09-24 CR CR9392A patent/CR9392A/es not_active Application Discontinuation
- 2007-09-28 ZA ZA200708323A patent/ZA200708323B/xx unknown
-
2010
- 2010-04-30 US US12/771,350 patent/US20100221445A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008534592A5 (enExample) | ||
| EP1833467B1 (en) | Pharmaceutical compositions for sleep disorders | |
| US8969400B2 (en) | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound | |
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| CN110944638A (zh) | 尼拉帕尼组合物 | |
| JP2005515964A5 (enExample) | ||
| JP2013529665A5 (enExample) | ||
| RU2007132852A (ru) | Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение | |
| JP2005530787A5 (enExample) | ||
| CA2507002A1 (en) | Solid drug for oral use | |
| JP2008512426A5 (enExample) | ||
| WO2018193648A1 (ja) | アルカリ性化剤による血液浄化 | |
| CA2577740A1 (en) | Method of enhancing absorptions of transmucosal administration formulations | |
| WO2010009618A1 (zh) | 用于治疗高血压和代谢综合症的药物组合物及其应用 | |
| RU2006135124A (ru) | Фармацевтические композиции толперизона контролируемого высвобождения, предназначенные для перорального введения | |
| TWI701043B (zh) | 包含血管收縮素-II受體阻斷劑及ＨＭＧ-ＣｏＡ還原酶抑制劑之醫藥組合製劑及其製備方法 | |
| WO2007048332A1 (fr) | Composition pharmaceutique pour le traitement de la goutte et sa preparation et son utilisation | |
| CN110799214A (zh) | 利用碱化剂的血液净化 | |
| JP4542777B2 (ja) | 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用 | |
| JP2013199506A (ja) | 処置方法 | |
| TW202341997A (zh) | 用於治療腸胃疾病或病狀之神經活性類固醇 | |
| JP2007529564A5 (enExample) | ||
| JP2009512705A5 (enExample) | ||
| WO2010009619A1 (zh) | 用于治疗高血压和代谢综合症的药物组合物及其应用 | |
| TW201206432A (en) | Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof |